COMPUGEN LTD (CGEN) Stock Price, Quote, News and Overview
NASDAQ:CGEN - Nasdaq - IL0010852080 - Common Stock - Currency: USD
CGEN Quote, Performance and Key Statistics
NASDAQ:CGEN (4/25/2025, 8:00:00 PM)
1.48
0 (0%)
The current stock price of CGEN is 1.48 USD. In the past month the price decreased by -2.63%. In the past year, price decreased by -22.92%.
CGEN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About CGEN
Company Profile
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Company Info
COMPUGEN LTD
Azrieli Center, 26 Harokmim St., Bldg D
Holon 5885849 IL
CEO: Anat Cohen-Dayag
Employees: 68
Company Website: https://cgen.com/
Investor Relations: https://ir.cgen.com
Phone: 97237658585
COMPUGEN LTD / CGEN FAQ
What is the stock price of COMPUGEN LTD today?
The current stock price of CGEN is 1.48 USD.
What is the ticker symbol for COMPUGEN LTD stock?
The exchange symbol of COMPUGEN LTD is CGEN and it is listed on the Nasdaq exchange.
On which exchange is CGEN stock listed?
CGEN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for COMPUGEN LTD stock?
10 analysts have analysed CGEN and the average price target is 4.85 USD. This implies a price increase of 227.36% is expected in the next year compared to the current price of 1.48. Check the COMPUGEN LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COMPUGEN LTD worth?
COMPUGEN LTD (CGEN) has a market capitalization of 132.52M USD. This makes CGEN a Micro Cap stock.
How many employees does COMPUGEN LTD have?
COMPUGEN LTD (CGEN) currently has 68 employees.
What are the support and resistance levels for COMPUGEN LTD (CGEN) stock?
COMPUGEN LTD (CGEN) has a support level at 1.26 and a resistance level at 1.49. Check the full technical report for a detailed analysis of CGEN support and resistance levels.
Is COMPUGEN LTD (CGEN) expected to grow?
The Revenue of COMPUGEN LTD (CGEN) is expected to decline by -30.62% in the next year. Check the estimates tab for more information on the CGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy COMPUGEN LTD (CGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CGEN, evaluating the profitability, health, valuation and growth aspects
- COMPUGEN LTD (CGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COMPUGEN LTD (CGEN) Sales and EPS estimates to see what analysts future expectations are.
- COMPUGEN LTD (CGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COMPUGEN LTD (CGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- COMPUGEN LTD (CGEN) Stock Chart to make your own analysis
- COMPUGEN LTD (CGEN) Latest news and press-releases to stay up to date.
Does COMPUGEN LTD (CGEN) stock pay dividends?
CGEN does not pay a dividend.
When does COMPUGEN LTD (CGEN) report earnings?
COMPUGEN LTD (CGEN) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of COMPUGEN LTD (CGEN)?
COMPUGEN LTD (CGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.16).
What is the Short Interest ratio of COMPUGEN LTD (CGEN) stock?
The outstanding short interest for COMPUGEN LTD (CGEN) is 2.21% of its float. Check the ownership tab for more information on the CGEN short interest.
CGEN Technical Analysis
CGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CGEN. While CGEN seems to be doing ok healthwise, there are quite some concerns on its profitability.
CGEN Financial Highlights
Over the last trailing twelve months CGEN reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 27.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.38% | ||
| ROE | -25.92% | ||
| Debt/Equity | 0 |
CGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to CGEN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 25.62% and a revenue growth -30.62% for CGEN